Market Herald logo


Be the first with the news that moves the market
  • Imugene has received a US Department of Defense grant for stomach cancer research
  • Almost $600,000 will be granted to Imugene researchers and City of Hope — a cancer research and treatment centre in the States
  • The studies will focus on treating a specific type of stomach cancer which affects soldiers more than the average person
  • The cause of this cancer in soldiers and veterans is likely due to their exposure to risky environments and radiation when out in the field
  • Imugene is up almost 5 per cent today, currently selling shares for 2.2 cents each

Imugene has been backed by the U.S. Department of Defense today with a $564,000 grant for its stomach cancer treatment.

The grant will help researchers from City of Hope — a cancer research and treatment centre in the States — study the effects of an Imugene cancer treatment in a specific type of stomach cancer known as peritoneal carcinomatosis (PC).

PC is an evolved form of stomach cancer for which there is currently no effective treatment. Moreover, this type of cancer disproportionately affects soldiers and veterans — hence the Department of Defense backing.

According to Imugene, the likely cause for the increased rate of stomach cancer in soldiers is their exposure to hazardous environments when out in the field, including radiation and certain bacteria.

Imugene’s potential treatment for this cancer involves the use of a specific virus, known simply as CF33, to kill the cancer cells while ignoring healthy cells.

Imugene CEO and Managing Director Leslie Chong said the company is committed to improving both the length and quality of life for stomach cancer sufferers.

“It is an honour to work with the prestigious and prolific team at City of Hope to expand the development of CF33,” Leslie said.

The CF33 virus treatment is designed to infect, replicate in, and then kill cancer cells. According to Imugene, the cancer cells that generally develop a resistance to chemo and radiation therapy — like PC cells — are more responsive to this type of viral treatment than other cancers.

With the first cancer treatment of this kind recently gaining U.S. Food and Drug Administration (FDA) approval, Imugene and now City of Hope are ready to build on the preclinical data for CF33, which showed positive results.

Imugene is up almost 5 per cent on the market today, currently selling shares for 2.2 cents each in a market cap valued at $75.93 million.

IMU by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.